Literature DB >> 27603293

Differences in virologic and immunologic response to antiretroviral therapy among HIV-1-infected infants and children.

Kristjana H Ásbjörnsdóttir1, James P Hughes, Dalton Wamalwa, Agnes Langat, Jennifer A Slyker, Hellen M Okinyi, Julie Overbaugh, Sarah Benki-Nugent, Kenneth Tapia, Elizabeth Maleche-Obimbo, Ali Rowhani-Rahbar, Grace John-Stewart.   

Abstract

BACKGROUND: Virologic and immunologic responses to antiretroviral treatment (ART) in infants may differ from older children due to immunologic, clinical, or epidemiologic characteristics.
METHODS: Longitudinal ART responses were modeled and compared in HIV-infected infants and children enrolled in cohorts in Nairobi, Kenya. Participants were enrolled soon after HIV diagnosis, started on ART, and followed for 2 years. Viral load decline was compared between infant and child cohorts using a nonlinear mixed effects model and CD4% reconstitution using a linear mixed effects model.
RESULTS: Among 121 infants, median age at ART was 3.9 months; among 124 children, median age was 4.8 years. At baseline, viral load was higher among infants than children (6.47 vs. 5.91 log10 copies/ml, P < 0.001). Infants were less likely than children to suppress viral load to less than 250 copies/ml following 6 months of ART (32% infants vs. 73% children, P < 0.0001). CD4% was higher at baseline in infants than children (19 vs. 7.3%, P < 0.001). Older children had more rapid CD4% reconstitution than infants, but failed to catch up to infant CD4%.
CONCLUSION: Despite substantially higher CD4% at ART initiation, viral suppression was significantly slower among infants than older children. New strategies are needed to optimize infant outcomes on ART.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27603293      PMCID: PMC5101154          DOI: 10.1097/QAD.0000000000001244

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  50 in total

1.  Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy.

Authors:  Dalton Wamalwa; Sarah Benki-Nugent; Agnes Langat; Kenneth Tapia; Evelyn Ngugi; Helen Moraa; Elizabeth Maleche-Obimbo; Vincent Otieno; Irene Inwani; Barbra A Richardson; Bhavna Chohan; Julie Overbaugh; Grace C John-Stewart
Journal:  AIDS       Date:  2016-09-24       Impact factor: 4.177

2.  Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.

Authors:  Theodore D Ruel; Abel Kakuru; Gloria Ikilezi; Florence Mwangwa; Grant Dorsey; Philip J Rosenthal; Edwin Charlebois; Diane Havlir; Moses Kamya; Jane Achan
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

3.  Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy.

Authors:  A Anselmi; D Vendrame; O Rampon; C Giaquinto; M Zanchetta; A De Rossi
Journal:  Clin Exp Immunol       Date:  2007-10-22       Impact factor: 4.330

4.  Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.

Authors:  Andrew Prendergast; Wendy Mphatswe; Gareth Tudor-Williams; Mpho Rakgotho; Visva Pillay; Christina Thobakgale; Noel McCarthy; Lynn Morris; Bruce D Walker; Philip Goulder
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

5.  Natural history of vertically acquired human immunodeficiency virus-1 infection. The European Collaborative Study.

Authors: 
Journal:  Pediatrics       Date:  1994-12       Impact factor: 7.124

6.  Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting.

Authors:  Kunjal Patel; Miguel A Hernán; Paige L Williams; John D Seeger; Kenneth McIntosh; Russell B Van Dyke; George R Seage
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

7.  Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.

Authors:  Thanyawee Puthanakit; Stephen Kerr; Jintanat Ananworanich; Torsak Bunupuradah; Pitch Boonrak; Virat Sirisanthana
Journal:  Pediatr Infect Dis J       Date:  2009-06       Impact factor: 2.129

Review 8.  Optimization of antiretroviral therapy in HIV-infected children under 3 years of age: a systematic review.

Authors:  Martina Penazzato; Andrew J Prendergast; Lulu M Muhe; Denis Tindyebwa; Elaine J Abrams
Journal:  AIDS       Date:  2014-03       Impact factor: 4.177

9.  Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.

Authors:  Marie-Quitterie Picat; Joanna Lewis; Victor Musiime; Andrew Prendergast; Kusum Nathoo; Addy Kekitiinwa; Patricia Nahirya Ntege; Diana M Gibb; Rodolphe Thiebaut; A Sarah Walker; Nigel Klein; Robin Callard
Journal:  PLoS Med       Date:  2013-10-29       Impact factor: 11.069

Review 10.  International perspectives, progress, and future challenges of paediatric HIV infection.

Authors:  Andrew Prendergast; Gareth Tudor-Williams; Prakash Jeena; Sandra Burchett; Philip Goulder
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

View more
  10 in total

1.  High Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected Children.

Authors:  Sarah F Benki-Nugent; Ira Martopullo; Tony Laboso; Nancy Tamasha; Dalton C Wamalwa; Kenneth Tapia; Agnes Langat; Elizabeth Maleche-Obimbo; Christina M Marra; Paul Bangirana; Michael J Boivin; Grace C John-Stewart
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

2.  Predictors of Early ART Initiation Among HIV + Infants in Kenya: A Retrospective Review of HITSystem Data from 2013 to 2017.

Authors:  Catherine Wexler; Niaman Nazir; Brad Gautney; May Maloba; Melinda Brown; Kathy Goggin; Raphael Lwembe; Sarah Finocchario-Kessler
Journal:  Matern Child Health J       Date:  2020-06

3.  Piloting the Feasibility and Preliminary Impact of Adding Birth HIV Polymerase Chain Reaction Testing to the Early Infant Diagnosis Guidelines in Kenya.

Authors:  Sarah Finocchario-Kessler; Catherine Wexler; Melinda Brown; Kathy Goggin; Raphael Lwembe; Niaman Nazir; Brad Gautney; Samoel Khamadi; Shadrack Babu; Elizabeth Muchoki; Nicodemus Maosa; Natabhona Mabachi; Yvonne Kamau; May Maloba
Journal:  Pediatr Infect Dis J       Date:  2021-08-01       Impact factor: 2.129

4.  Scale-up of Kenya's national HIV viral load program: Findings and lessons learned.

Authors:  Matilu Mwau; Catherine Akinyi Syeunda; Maureen Adhiambo; Priska Bwana; Lucy Kithinji; Joy Mwende; Laura Oyiengo; Martin Sirengo; Caroline E Boeke
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

5.  HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.

Authors:  Chloe A Teasdale; Nonzwakazi Sogaula; Katharine A Yuengling; Chunhui Wang; Anthony Mutiti; Stephen Arpadi; Mahlubandile Nxele; Lungile Pepeta; Mary Mogashoa; Emilia D Rivadeneira; Elaine J Abrams
Journal:  J Int AIDS Soc       Date:  2018-08       Impact factor: 5.396

6.  Viral suppression among children and their caregivers living with HIV in western Kenya.

Authors:  John M Humphrey; Becky L Genberg; Alfred Keter; Beverly Musick; Edith Apondi; Adrian Gardner; Joseph W Hogan; Kara Wools-Kaloustian
Journal:  J Int AIDS Soc       Date:  2019-04       Impact factor: 6.707

7.  Predictors of faster virological suppression in early treated infants with perinatal HIV from Europe and Thailand.

Authors: 
Journal:  AIDS       Date:  2019-06-01       Impact factor: 4.177

8.  Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat".

Authors:  Joseph Fokam; Samuel Martin Sosso; Bouba Yagai; Serge Clotaire Billong; Rina Estelle Djubgang Mbadie; Rachel Kamgaing Simo; Serge Valery Edimo; Alex Durand Nka; Aline Tiga Ayissi; Junie Flore Yimga; Désiré Takou; Sylvie Moudourou; Marinette Ngo Nemb; Jean-Bosco Nfetam Elat; Maria-Mercedes Santoro; Carlo-Federico Perno; Vittorio Colizzi; Alexis Ndjolo
Journal:  AIDS Res Ther       Date:  2019-11-19       Impact factor: 2.250

9.  The effect of antiretroviral therapy initiation on vitamin D levels and four oral diseases among Kenyan children and adolescents living with HIV.

Authors:  Ana Lucia Seminario; Arthur Kemoli; Walter Fuentes; Yan Wang; Poojashree Rajanbabu; Dalton Wamalwa; Sarah Benki-Nugent; Grace John-Stewart; Jennifer A Slyker
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

10.  Time to Viral Suppression in Perinatally HIV-Infected Infants Depends on the Viral Load and CD4 T-Cell Percentage at the Start of Treatment.

Authors:  Juliane Schröter; Anet J N Anelone; Andrew J Yates; Rob J de Boer
Journal:  J Acquir Immune Defic Syndr       Date:  2020-04-15       Impact factor: 3.771

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.